Last reviewed · How we verify

Dexanabinol Dose Level 3

e-Therapeutics PLC · Phase 1 active Small molecule ✓ Verified May 2026

Dexanabinol Dose Level 3 is a Small molecule drug developed by e-Therapeutics PLC. It is currently in Phase 1 development. Also known as: ETS2101.

Dexanabinol is being studied in a Phase 1b clinical trial (NCT02423239) for its safety and anti-tumor activity in patients with advanced tumors, including Hepatocellular Carcinoma, Pancreatic Cancer, and Brain Cancer. The study involves administering Dexanabinol in combination with chemotherapy, specifically Nab-paclitaxel, to assess its effects.

Likelihood of approval
9.6% vs 9.6% industry baseline
If approved by FDA: likely 2033–2036
Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission
Confidence: Medium
Why this estimate
  • Baseline phase 1 → approval rate +9.6pp
    Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2033–2036 —
EMA EU 2034–2037 +0.7 yr
MHRA GB 2034–2037 +0.7 yr
Health Canada CA 2034–2038 +0.9 yr
TGA AU 2034–2038 +1.2 yr
PMDA JP 2034–2038 +1.5 yr
NMPA CN 2035–2039 +2.3 yr
MFDS KR 2034–2038 +1.4 yr
CDSCO IN 2034–2039 +1.8 yr
ANVISA BR 2035–2039 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameDexanabinol Dose Level 3
Also known asETS2101
Sponsore-Therapeutics PLC
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Dexanabinol Dose Level 3

What is Dexanabinol Dose Level 3?

Dexanabinol Dose Level 3 is a Small molecule drug developed by e-Therapeutics PLC.

Who makes Dexanabinol Dose Level 3?

Dexanabinol Dose Level 3 is developed by e-Therapeutics PLC (see full e-Therapeutics PLC pipeline at /company/e-therapeutics-plc).

Is Dexanabinol Dose Level 3 also known as anything else?

Dexanabinol Dose Level 3 is also known as ETS2101.

What development phase is Dexanabinol Dose Level 3 in?

Dexanabinol Dose Level 3 is in Phase 1.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing